Our sponsors are fundamental to the success of the IOIS Congress and once again we’d like to extend our special thanks to all of our sponsors. Without them we would not be able to organize the congress.

Satellite Symposium by ALIMERA SCIENCES
Thursday, June 26, 2025 - 13:15-14:05 - Gavea B

Traffic Lights in NIU-PS – An EU expert user guideline on long-acting intravitreal implant. Case studies with panel discussion.

Chairmen: Professor Quan Dong Nguyen, Byers Eye Institute, California, USA

12:55	Welcome and Introductions
	Professor Quan Dong Nguyen
12:58	Optimizing Treatment for Recurrent Non-infectious Uveitis: Evidence from PSV-FAi-001 and PSV-FAi-005
	Professor Carlos Pavesio
13:03	Navigating Treatment Decisions in NIU-PS: A Traffic Light Approach with the 0.2 µg/day Fluocinolone Acetonide Intravitreal Implant
	Professor Uwe Pleyer
13:08	NIU-PS case 1 presentation
	Ms Ilaria Testi
13:14	NIU-PS case 2 presentation
	Ms Sarah Touhami
13:20	NIU-PS case 3 presentation
	Mr Will Tucker
13:26	NIU-PS case 4 presentation
	speaker tbc
13:32	NIU-PS case 5 presentation
	speaker tbc
13:38	Conclusions
	Professor Quan Dong Nguyen
13:45	END OF SYMPOSIUM

Satellite Symposium by KODIAK Sciences Inc.
Friday, June 27, 2025 - 07:00-07:50 - Gavea B

A First-in-Class Investigational Bispecific Protein for Macular Edema Secondary to Inflammation (MESI): Clinical Cases and Expert Panel Insights

Chairmen: Prof. Quan Dong Nguyen, MD, Msc

07:00	Welcome and Introductions
	Quan Dong Nguyen, MD, MSc, Stanford Byers Eye Institute, USA
07:05	Kodiak Sciences Today
	Victor Perlroth, MD – CEO of Kodiak Sciences
07:15	KSI-101 Biology and Rationale
	Lyndell Lim, MBBS , DMedSci – Professor at Center for Eye Research, Australia
07:20	Introducing Macular Edema Secondary to Inflammation (MESI) and APEX Phase 1b Case Examples
	De-Kuang Hwang (DK ) MD, PhD – Associate Professor Division Director, Department of Ophthalmology, Taipei Veterans General Hospital. National Yang Ming Chiao Tung University, Taiwan
07:30	Phase 3 Program in MESI: PEAK and Pinnacle Study Design
	Ariel Schlaen, MD, PhD Director Hospital Universitario Austral, Argentina
07:35	Panelist discussion and Q&A
07:50	END OF SYMPOSIUM

Satellite Symposium by PROVIANT Therapeutics
Friday, June 27, 2025 - 12:55-13:45 - Gavea B

A Potential New Oral Therapy (JAK inhibitor) for Non-Infectious Uveitis: Results from Phase 2 Study (NEPTUNE) and Progress from Phase 3 Study (CLARITY)
hosted by Priovant Therapeutics

Chairmen: Mr Scott Jones - Proviant Therapeutics

12:55	Rationale for brepocitinib in NIU, results from Phase 2 study, progress on Phase 3 study
	Prof. Quan Dong Nguyen, Stanford Byers Eye Institute
13:15	Introduction to Priovant, background on brepocitinib (moderator)
	Mr. Scott Jones, Priovant Therapeutics
13:25	Panel of CLARITY Study Investigators
	Moderated by Scott Jones
13:25	Discussion of JAK inhibition in NIU, design and implementation of the Phase 3 study, and taking questions from the audience.
	Dr Quan Nguyen, Stanford Byers Eye Institute, USA Dr Elisabetta Miserocchi, Universita Via-Salute San Raffaele, Italy Dr Ariel Schlaen, Hospital Universitario Austral, Argentina Dr Nima Ghadiri, Liverpool University Hospital NHS Foundation Trust, UK Scott Jones, Priovant Therapeutics, moderator
13:45	END OF SYMPOSIUM

THANK YOU SPONSORS
IOIS 2025 was made possible thanks to the support of the following companies: